Lacrisifi (Lacrisifi)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceBenzalkonium chloride + HypromelloseBenzalkonium chloride + Hypromellose
Similar drugsTo uncover
  • Lacrisifi
    drops d / eye 
    SIIFI SpA     Italy
    • Dosage form: & nbsp

    eye drops

    Composition:

    Per 100 ml:

    Active substances: hypromellose 0.500 g, benzalkonium chloride 0.010 g.

    Excipients: sodium hydrogen phosphate dodecahydrate 2.2 g; sodium dihydrogen phosphate monohydrate 2,265 g; sodium chloride 0.2 g; disodium edetate 0.1 g; water purified to 100 ml.

    Description:Transparent colorless or slightly yellowish tinge solution.
    Pharmacotherapeutic group:Keratoprotective agent
    ATX: & nbsp

    S.01.X.A   Other drugs for the treatment of eye diseases

    S.01.X.A.20   Artificial tears and other indifferent drugs

    Pharmacodynamics:

    Hypromellose is a protector of the epithelium of the cornea, having a high viscosity, increases the duration of contact of the solution with the cornea. The refractive index of the solution is similar to natural tears.

    Recovers, stabilizes and reproduces optical characteristicssticks of tear film. Extends the effect of other eye drops and protects the cornea from their irritating effect.

    Benzalkonium chloride - has a disinfection effect and some properties of cationic detergents. Has a bactericidal effect against gram-positive microorganisms, some yeast fungi. Less active with respect to P. aerugenosa, M. tuberculosis, Clostridia spp., Sporogenous microorganisms and viruses.

    Pharmacokinetics:Absorption of benzalkonium chloride is limited.
    Indications:

    Insufficient lacrimation, lagophthalmus, eyelid deformation, ectropion, condition after plastic surgery on the eyelids, erosion and trophic ulcers of the cornea, condition after surgical and thermal burns of the cornea and conjunctiva, bullous dystrophic changes of the cornea, keratopathy, microdefects of the corneal epithelium, condition after keratoplasty, keratoectomy.

    Necessity of prolonging the effect or reducing the irritating effect of other eye drops. Combined treatment of the "dry eye" syndrome: Sjogren's syndrome, xerosis, keratosis (often in combination with therapeutic contact lenses).

    Eye irritation caused by smoke, dust, cold, wind, sun, salt water, with allergies.

    Conducting diagnostic procedures: gonioscopy, electroretinography, electrooculography, ultrasound.

    Contraindications:

    Individual hypersensitivity to the components of the drug, acute inflammatory and infectious diseases of the anterior part of the eye.

    Pregnancy, the period of breastfeeding, children's age.
    Carefully:In the acute phase of a chemical burn of the cornea and conjunctiva (until the complete removal of toxic substances and necrotic tissues).
    Dosing and Administration:

    Bury 1 to 2 drops 4-8 times a day in a conjunctival sac. Do not exceed the recommended dose.

    When appointing the drug for the treatment of the "dry eye" syndrome, the duration of treatment is determined by the doctor.

    When appointing a drug with an antimicrobial purpose, the period of application is 5-7 days.

    Side effects:

    Allergic reactions, the feeling of gluing the eyelids (due to the high viscosity of the solution), a feeling of burning or irritation.

    The development of allergic reactions is possible with prolonged use of the drug. In this case, discontinuation of treatment and the appointment of appropriate therapy are indicated.

    With prolonged use, it is possible to develop dystrophic changes in the epithelium of the cornea.

    Overdose:

    There is no information about drug overdose.

    Interaction:The drug is incompatible with eye drops containing metal salts.
    Special instructions:

    The drug is not recommended for use with contact lenses. Before using the drug, remove contact lenses and re-dress them no earlier than 20-30 minutes.

    Effect on the ability to drive transp. cf. and fur:In view of possible lacrimation after instillation of the drug, it is not recommended to apply it directly before driving vehicles or servicing mechanical equipment.
    Form release / dosage:

    Eye drops.

    Packaging:To 10 ml of solution in bottles-droppers of low-density polyethylene (LDPE) with lids made of white polystyrene. For 1 bottle together with instructions for medical use in a pack of cardboard.
    Storage conditions:At a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    After opening the vial, the drug should be used within 28 days. Do not use after the expiry date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:П N014750 / 01
    Date of registration:10.10.2008
    Expiration Date:Unlimited
    The owner of the registration certificate:SIIFI SpASIIFI SpA Italy
    Manufacturer: & nbsp
    Representation: & nbspNovaMedika, OOONovaMedika, OOORussia
    Information update date: & nbsp10.02.2018
    Illustrated instructions
      Instructions
      Up